Cytokinetics, Incorporated (CYTK)
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM
Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise capacity.
Cytokinetics eyes expanded use of heart drug after promising late-stage data
Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly improved symptoms and exercise capacity in patients with a genetic heart condition that currently has no approved treatments.
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings.
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.
Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript
Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript
Cytokinetics Q2 Earnings Call Highlights
Cytokinetics NASDAQ: CYTK reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten in non-obstructive hypertrophic cardiomyopathy, or nHCM.
Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to a loss of $1.12 per share a year ago.
Cytokinetics wins UK approval, NICE backing for heart disease drug
Britain's medicines regulator approved Cytokinetics' drug for a rare heart condition on Thursday, with the country's cost-effectiveness watchdog recommending it for NHS reimbursement, potentially reaching about 6,600 patients.
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise
Cytokinetics (CYTK) is positioned to expand MYQORZO across the entire HCM continuum, not just as a late-stage competitor to Camzyos. Initial MYQORZO launch metrics—rapid market access, >30% new-to-brand share, and strong prescriber uptake—signal robust commercial traction beyond headline Q1 revenue. MAPLE-HCM and ACACIA-HCM trials support earlier use and a potential doubling of the addressable market via non-obstructive HCM, driving CYTK's long-term value.
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
